Combined Effects of the Hedgehog Pathway Inhibitor LDE225 and Nilotinib In a Random Mutagenesis Screen
Authors: Tauchi Tetsuzo , Okabe Seiichi , Ashihara Eishi , Kimura Shinya , Maekawa Taira , Ohyashiki Kazuma 
Published: October 2019

Abstract
Abstract 595
The hedgehog signaling pathway is a developmental pathway that has been shown to play a role in primitive hematopoiesis. Recent studies have demonstrated that hedgehog pathway is activated in chronic myeloid leukemia (CML) stem cells via up-regulation of Smoothened (Smo), a seven transmembrane domain receptor protein. LDE225 is a small molecule Smo antagonist which has entered Phase I clinical evaluation in patients with solid tumors. In the present study, we investigated the combined effects of LDE225 and nilotinib in a random mutagenesis study for BCR-ABL mutation (Blood, 109; 5011, 2007). We performed a comprehensive drug combination experiment using a broader range of concentrations for LDE225 and nilotinib. Compared with single agents, the combination of LDE225 and nilotinib was more effective at reducing the outgrowth of resistant cell clones. No outgrowth was observed in the presence of 2 μM nilotinib plus 20 μM LDE225. Also co-treatment with LDE225 and nilotinib resulted in significantly more inhibition of growth than treatment with either agent alone in BaF3 cells expressing wt-BCR-ABL and BCR-ABL mutants (M244V, G250E, Q252H, Y253F, E255K, T315A, T315I, F317L, F317V, M351T, H396P). The observed data from the isobologram indicated the synergistic effect of simultaneous exposure to LDE225 and nilotinib even in BaF3 cells expressing T315I. Co-treatment with 2μM of nilotinib significantly increased LDE225-induced apoptosis in BaF3 cells expressing T315I. Combined treatment with LDE225 and nilotinib in BaF3 T315I also associated with more PARP cleavage, resulting from increased activation of caspase-3 and -9 during apoptosis. To assess the mechanism of combination effect between LDE225 and nilotinib on T315I BCR-ABL-expressing cells, we used RNA interference to determine whether reduction of nilotinib off-target affected the growth inhibition. BaF3 cells expressing T315I BCR-ABL pretreated with DDR1 siRNA showed enhanced growth inhibition with LDE225. These results demonstrate that the enhanced growth inhibition by LDE225 and nilotinib in T315I-expressing cells may be mediated by DDR1. To assess the in vivo efficacy of LDE225 and nilotinib, athymic nude mice were injected s.c. with BaF3 cells expressing random mutagenesis for BCR-ABL mutation. 7 days after injection (average tumor volume, 100 mm3), the mice were randomised into four groups (5 mice per group), with each group receiving either vehicle, LDE225 (20mg/kg; p.o. once every day), nilotinib (30mg/kg; p.o. once every day), LDE225 (20mg/kg; p.o. once every day) + nilotinib (30mg/kg; p.o. once every day). The LDE225 and nilotinib combination more effectively inhibited tumor growth in mice compared to either vehicle- or nilotinib- or LDE225-treated mice. Histopathologic analysis of tumor tissue from LDE225 plus nilotinib-treated mice demonstrated an increased number of apoptotic cells detected by TUNEL staining. To investigate combined effects of LDE225 and nilotinib on primary Ph-positive acute lymphocytic leukemia (ALL) cells, NOD/SCID mice were injected i.v. with bone marrow mononuclear cells from a Ph positive ALL patient. Treatment with LDE225 and nilotinib demonstrated a marked segregation of apoptotic cells in both the central bone-marrow cavity and the endosteal surface. These results suggest that the combination with a Smo inhibitor and ABL TKIs may help to eliminate the Ph positive ALL cells. Taken together, the present study shows that the combination of LDE225 and nilotinib exhibits a desirable therapeutic index that can reduce the in vivo growth of mutant forms of BCR-ABL-expressing cells.

Disclosures:
Tauchi: Novartis Pharma KK: Research Funding.